Prophylactic application of modified vacuum-assisted closure therapy in Ivor Lewis esophagectomy: Preliminary results
World Journal of Gastrointestinal Surgery · 2026-11-27 · 18 (11)
DOI: 10.4240/wjgs.124340 ↗Abstract
BACKGROUND Ivor Lewis esophagectomy is the standard surgical approach for middle and distal esophageal cancer. Despite advances in minimally invasive techniques and perioperative care, anastomotic leakage (AL) remains a major cause of postoperative morbidity and mortality. Although prophylactic endoluminal vacuum therapy has shown promise, its clinical use is limited by procedural complexity and cost. AIM To evaluate the feasibility, safety, and preliminary clinical outcomes of a modified, endoscopy-independent prophylactic vacuum-assisted closure system (ModVAC) in patients undergoing Ivor Lewis esophagectomy. METHODS This retrospective single-center study included 31 patients who underwent Ivor Lewis esophagectomy from July 2019 to June 2024. Sixteen patients received prophylactic ModVAC therapy, while fifteen earlier patients served as historical controls. The primary outcome was AL. RESULTS Baseline characteristics were comparable between groups. AL occurred in 25% vs 40% of patients (P = 0.37), with all ModVAC leaks managed non-operatively. Hospital stay, morbidity, and mortality were similar. Protocol completion was 81.25% with minimal device-related complications. CONCLUSION Prophylactic ModVAC is a feasible and safe adjunct following Ivor Lewis esophagectomy. Although leak reduction was not statistically significant, the favorable management of leaks suggests potential clinical benefit. Larger prospective randomized studies are warranted.
EUVIMED